A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Active, not recruiting
Phase 3

Conditions

Psoriatic Arthritis

Treatments

Drug: Apremilast
Other: Placebo
Drug: Deucravacitinib

Study type

Interventional

Funder types

Industry

Identifiers

NCT04908189
IM011-055
U1111-1259-9466 (Registry Identifier)
2020-005099-36 (EudraCT Number)

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.

Enrollment

700 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Diagnosed to have psoriatic arthritis (PsA) of at least 3 months duration at Screening
  • Meets the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria at Screening
  • Active plaque psoriatic skin lesion(s) or documented medical history of plaque psoriasis (PsO) at Screening
  • Active arthritis as shown by ≥ 3 swollen joints and ≥ 3 tender joints at Screening and Day 1
  • Participant has high sensitivity C-reactive protein (hsCRP) ≥ 3 mg/L at Screening
  • Must have completed the week 52 treatment for the optional open-label long-term extension period

Exclusion criteria

  • Nonplaque psoriasis at Screening or Day 1
  • Other autoimmune condition such as systemic lupus erythematous, mixed connective tissue disease, multiple sclerosis, or vasculitis
  • History of or current inflammatory joint disease other than PsA (e.g., gout, reactive arthritis, rheumatoid arthritis, ankylosing spondylitis, Lyme disease)
  • Active fibromyalgia
  • Received an approved or investigational biologic therapy for the treatment of PsA or PsO

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

700 participants in 3 patient groups, including a placebo group

Deucravacitinib
Experimental group
Treatment:
Drug: Deucravacitinib
Placebo
Placebo Comparator group
Treatment:
Drug: Deucravacitinib
Other: Placebo
Apremilast
Other group
Treatment:
Drug: Apremilast

Trial contacts and locations

152

Loading...

Central trial contact

BMS Study Connect Contact Center www.BMSStudyConnect.com; First line of email MUST contain NCT # and site #.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems